Hyposensitization in asthmatics with mPEG-modified and unmodified house dust mite extract. IV. Occurrence and prediction of side effects.
A double-blind study on hyposensitization (HS) with two extracts prepared from the house dust mite Dermatophagoides pteronyssinus (Dp) was performed on a group of asthmatics with bronchial sensitivity to Dp. In 18 patients, aluminium-hydroxide was added to the Dp-extract to give a depot effect (Dp-group). Nineteen patients were treated with a similar extract in which allergenicity had been reduced by coupling to monomethoxypolyethylene glycol (mPEG-Dp-group). This extract had previously been shown to have less effect on clinical symptoms and skin sensitivity compared to the Dp-extract. In the Dp- and mPEG-Dp-groups, 778 and 675 injections were administered. Fifteen and 12 patients in the Dp- and mPEG-Dp-groups had systemic reactions (P greater than 0.05). The frequency of injections giving systemic reactions was reduced in the mPEG-Dp-group: 5.1% compared to 9.0% in the Dp-group (P less than 0.01). In the mPEG-Dp-group, reactions were mild to moderate, mainly late-occurring asthma and urticaria, whereas two episodes of anaphylaxis and four of severe asthma occurred in the Dp-group. The reduction in side effects seems promising, but a further dose increase in the mPEG-Dp-group would be necessary to compare the side effects of doses with equal therapeutic effectiveness. High frequency of late local reactions made dose increase impossible with the present slightly modified extract. The systemic side effects occurred more frequently in patients highly skin test-sensitive to Dp prior to treatment. All patients skin test-positive to less than or equal to 100 BU had systemic reactions. Systemic side effects could not be predicted from the size of previous local reactions.
Mosbech
H
H
Medical Dept., State University Hospital, Copenhagen, Denmark.
Dirksen
A
A
Dreborg
S
S
Frølund
L
L
Heinig
J H
JH
Svendsen
U G
UG
Søborg
M
M
Taudorf
E
E
Weeke
B
B
D000818:Animals; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D003888:Desensitization, Immunologic / Q000009:adverse effects* / Q000379:methods; D004306:Dose-Response Relationship, Immunologic; D004311:Double-Blind Method; D004391:Dust / Q000009:adverse effects*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007279:Injections, Subcutaneous; D008925:Mites / Q000276:immunology*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D004391:Dust; D011092:Polyethylene Glycols; C028210:monomethoxypolyethylene glycol